Molly C. v. Oxford Health Insurance, Inc.

District Court, S.D. New York·Decided January 4, 2023·No. 1:21-cv-10144·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK MOLLY C. and NAOMI L. STIPULATED CONFIDENTIALITY Plaintiffs, AGREEMENT AND PROTECTIVE ORDER -against - 1:21-cv-10144-PGG OXFORD HEALTH INSURANCE, INC. Defendant. PAUL G. GARDEPHE, U.S.D.J.: WHEREAS, all the Parties to this action (collectively the “Parties” and individually a “Party”) request that this Court issue a protective order pursuant to Federal Rule of Civil Procedure 26(c) to protect the confidentiality of nonpublic and competitively sensitive information that they may need to disclose in connection with discovery in this action; WHEREAS, the Parties, through counsel, agree to the following terms; and WHEREAS, this Court finds good cause exists for issuance of an appropriately tailored confidentiality order governing the pretrial phase of this action, IT IS HEREBY ORDERED that any person subject to this Order – including without limitation the Parties to this action (including their respective corporate parents, successors, and assigns), their representatives, agents, experts and consultants, all third parties providing discovery in this action, and all other interested persons with actual or constructive notice of this Order — will adhere to the following terms, upon pain of contempt: 1. With respect to “Discovery Material” (i.e., information of any kind produced or disclosed in the course of discovery or settlement discussions in this action) that a person has designated as “Confidential” or “Highly Confidential – Attorneys’ Eyes Only” (collectively “Designated Material”) pursuant to this Order, no person subject to this Order may disclose such Designated Material to anyone else except as this Order expressly permits. 2. The Party or person producing or disclosing Designated Material (“Producing Party”) may designate as “Confidential” only the portion of such material that it reasonably and in good faith believes consists of: (a) previously non-disclosed financial information (including without limitation profitability reports or estimates, percentage fees, design fees,

royalty rates, minimum guarantee payments, sales reports, and sale margins); (b) previously non-disclosed material relating to ownership or control of any non-public company; (c) previously non-disclosed business plans, product-development information, or marketing plans; (d) any information of a personal or intimate nature regarding any individual; or (e) any other category of information this Court subsequently affords confidential status.

3. The Party or person producing or disclosing Designated Material (“Producing Party”) may designate as “Highly Confidential – Attorneys’ Eyes Only” only the portion of such material that it reasonably and in good faith believes consists of extremely sensitive information, disclosure of which to another Party or Non-Party would create a substantial risk of serious harm that could not be avoided by less restrictive means. 4. The Parties acknowledge that Designated Material may contain personal health information (“PHI”) subject to the protections of the Standards for Privacy of Individually Identifiable Health Information, 45 C.F.R. parts 160 and 164, promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). 45 C.F.R. § 164.512 permits disclosure of PHI in response to a discovery request or other lawful process if, among other requirements, the parties to the dispute have agreed to a qualified protective order and have presented it to the court with jurisdiction over the dispute. 45 C.F.R. §164.512(e)(IV)(A). (a) The parties agree that Defendants will redact individually identifiable

information about the absent putative class members prior to producing PHI to the extent practicable, including the member names, addresses, dates of birth, social security numbers, and member or subscriber ID numbers. The parties recognize that the name of the members’ health plan, the date(s) and location of treatment; and date(s) of benefit coverage determination(s) may be relevant to the parties’ assessment of this case, and therefore agree that such information will not be redacted prior to production. In the event that those data constitute PHI, or in the event that any other PHI is disclosed within the unredacted portions of the Discovery Material, individual notice to the putative class members

is deemed to be impractical and inadvisable and good cause for the order exists. The parties shall be allowed to disclose such information to the opposing party. To further protect such PHI, any disclosure of this information shall be designated as “Highly Confidential – Attorneys’ Eyes Only” with the associated protections and restrictions set forth in this Stipulated Protective Order. 5. With respect to the “Confidential” or “Highly Confidential – Attorneys’ Eyes Only” portion of any Designated Material other than deposition transcripts and exhibits, the Producing Party or its counsel may designate such portion as “Confidential” or “Highly Confidential – Attorneys’ Eyes Only” by: (a) stamping or otherwise clearly marking as “Confidential” the protected portion in a manner that will not interfere with legibility or audibility; and (b) producing for future public use another copy of said Discovery Material with the confidential information redacted.

6. A Producing Party or its counsel may designate deposition exhibits or portions of deposition transcripts as “Confidential” or “Highly Confidential – Attorneys Eyes Only” either by: (a) indicating on the record during the deposition that a question calls for “Confidential” or “Highly Confidential – Attorneys’ Eyes Only” information, in which case the reporter will bind the transcript of the designated testimony in a separate volume and mark it as “Confidential Information Governed by Protective Order;” or (b) notifying the reporter and all counsel of record, in writing, within 30 days after a deposition has concluded, of the specific pages and lines of the transcript that are to be designated “Highly Confidential – Attorneys’ Eyes Only” or “Confidential,” in which case all counsel receiving the transcript will be

responsible for marking the copies of the designated transcript in their possession or under their control as directed by the Producing Party or that person’s counsel. During the 30-day period following a deposition, all Parties will treat the entire deposition transcript as if it had been designated “Confidential” or “Highly Confidential – Attorneys’ Eyes Only.” 7. If at any time before the trial of this action a Producing Party realizes that it should have designated as “Confidential” or “Highly Confidential – Attorneys’ Eyes Only” some portion(s) of Discovery Material that it previously produced without limitation, the Producing Party may so designate such material by so apprising all prior recipients in writing. Thereafter, this Court and all persons subject to this Order will treat such designated portion(s) of the Discovery Material as “Confidential” or “Highly Confidential – Attorneys’ Eyes Only.” 8. Nothing contained in this Order will be construed as: (a) a waiver by a Party or person of its right to object to any discovery request; (b) a waiver of any privilege or protection; or (c) a ruling regarding the admissibility at trial of any document, testimony, or other evidence. 9. Where a Producing Party has designated Discovery Material as “Confidential,” other persons subject to this Order may disclose such information only to

Free access — add to your briefcase to read the full text and ask questions with AI

Molly C. v. Oxford Health Insurance, Inc., (S.D.N.Y. 2023).

Molly C. v. Oxford Health Insurance, Inc. (Molly C. v. Oxford Health Insurance, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Lugosch v. Pyramid Co. of Onondaga
435 F.3d 110 (Second Circuit, 2006)